title: The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
abstract: Malignant pleural mesothelioma (MPM) is a rapidly progressive invariably lethal tumor. Treatment options remain limited and the outcome in relapsed disease is poor warranting new therapeutic options. Following our previous experience in the first-line setting, we conducted a phase 2 open-label non-comparative study to assess the safety and efficacy of weekly vinorelbine chemotherapy, each cycle consisting of 30 mg/m(2) for 6 weeks, in patients with previous exposure to chemotherapy. In 63 individuals with relapsed MPM who had not received previous vinorelbine, we observed an objective response rate of 16% and an overall survival of 9.6 months (95% confidence interval 7.3-11.8 months). The main grade III/IV toxicity observed was neutropenia and toxicity was similar to weekly vinorelbine when used in the first-line setting. Weekly vinorelbine appeared to have a reasonable response rate with an acceptable toxicity profile in the second-line treatment of MPM. Its use should be prospectively evaluated in a randomised trial in the first or second-line therapy of MPM.
authors.affiliation: Department of Medical Oncology, St. Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK. j.stebbing@imperial.ac.uk
authors.forename: Justin
authors.initials: J
authors.lastname: Stebbing
authors.forename: Thomas
authors.initials: T
authors.lastname: Powles
authors.forename: Kirsty
authors.initials: K
authors.lastname: McPherson
authors.forename: Jonathan
authors.initials: J
authors.lastname: Shamash
authors.forename: Paula
authors.initials: P
authors.lastname: Wells
authors.forename: Michael T
authors.initials: MT
authors.lastname: Sheaff
authors.forename: Sarah
authors.initials: S
authors.lastname: Slater
authors.forename: Robin M
authors.initials: RM
authors.lastname: Rudd
authors.forename: Dean
authors.initials: D
authors.lastname: Fennell
authors.forename: Jeremy P C
authors.initials: JP
authors.lastname: Steele
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000473:pathology*; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D000970:Antineoplastic Agents; D014747:Vinblastine; D000077235:Vinorelbine